Covered recipient · General Payments record
ANJUM ISMAIL
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
General Payments · PY2019–2025
$2,228.00
- Reported across 91 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $452.53 | 15 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $159.12 | 5 |
| CVRx Inc. | $101.15 | 3 |
| Medtronic, Inc. | $37.10 | 1 |
| ATRICURE, INC. | $33.16 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $29.47 | 1 |
| Alnylam Pharmaceuticals Inc. | $28.88 | 1 |
| Novo Nordisk AS | $22.33 | 1 |
| Inspire Medical Systems, Inc. | $22.12 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $19.20 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $25.03 | 06/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240656483 | CMS |
| Abbott Laboratories | $18.73 | 06/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240656900 | CMS |
| Abbott Laboratories | $8.65 | 06/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240656907 | CMS |
| Abbott Laboratories | $97.38 | 08/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240857317 | CMS |
| Abbott Laboratories | $9.33 | 09/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1240666416 | CMS |
| Alnylam Pharmaceuticals Inc. | $28.88 | 04/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1212789092 | CMS |
| AtriCure, Inc. | $33.16 | 07/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1223199709 | CMS |
| Boston Scientific Corporation | $19.20 | 11/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1181234730 | CMS |
| CVRx, Inc. | $31.03 | 06/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1219176960 | CMS |
| CVRx, Inc. | $37.57 | 07/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1220071372 | CMS |
| CVRx, Inc. | $32.55 | 10/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1223407558 | CMS |
| Inspire Medical Systems, Inc. | $22.12 | 09/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1251475957 | CMS |
| Medtronic, Inc. | $37.10 | 11/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1218918033 | CMS |
| Novartis Pharmaceuticals Corporation | $29.47 | 10/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1200257455 | CMS |
| Novo Nordisk Inc | $22.33 | 06/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189083527 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.